Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663313 | 1.00 | NAAA (0.40) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL5662495 | 1.00 | NAAA (0.40) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL6227914 | 0.79 | MTOR (0.37) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL5660885 | 0.79 | MTOR (0.37) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL6082708 | 0.79 | MTOR (0.37) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL5661778 | 0.78 | MTOR (0.35) | MTORADRA1A | |
| SCHEMBL5663243 | 0.78 | MTOR (0.35) | MTORADRA1A | |
| SCHEMBL19810282 | 0.75 | NAAA (0.57) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL18007116 | 0.75 | NAAA (0.57) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL18006656 | 0.72 | NAAA (0.54) | NAAANPC1LMNATP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | NAAA 4028/4885NPC1 186/4885LMNA 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.